Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $124

Benzinga Newsdesk www.benzinga.com Positive 83.2%

Neg 0% Neu 0% Pos 83.2%

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $119 to $124.